Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166161 | 0.89 | MAPT (0.40) | GPR119KDM4EMAPTTHRBHPGD | |
| SCHEMBL16698699 | 0.89 | GPR119 (0.42) | GPR119KDM4EMAPTTHRBHPGD | |
| SCHEMBL18153613 | 0.87 | MBOAT4 (0.39) | GPR119KDM4EMAPTTHRBHPGD | |
| SCHEMBL16049455 | 0.76 | MAP4K4 (0.44) | GPR119KDM4EMAPTTHRB | |
| SCHEMBL25258371 | 0.75 | GPR119 (0.44) | GPR119MAPT | |
| SCHEMBL20839829 | 0.75 | GPR119 (0.44) | GPR119KDM4EMAPTTHRBPTPN2 | |
| SCHEMBL29774310 | 0.75 | GPR119 (0.44) | GPR119KDM4EMAPTTHRBPTPN2 | |
| SCHEMBL22776493 | 0.75 | GPR119 (0.45) | GPR119KDM4E | |
| SCHEMBL20009391 | 0.74 | MBOAT4 (0.50) | GPR119KDM4EDPP4 | |
| SCHEMBL16040735 | 0.74 | GPR119 (0.40) | GPR119KDM4EMAPTTHRBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086732-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-29 | — | — | US | disclosed |
| US-20180086732-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | ELI LILLY AND COMPANY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086732-A1 | GHRELIN 0-ACYL TRANSFERASE INHIBITORS | MBOAT4, GIPR, PLAAT2 | GPR119 18/4885KDM4E 961/4885MAPT 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.